Results 111 to 120 of about 11,979 (257)

Tumor treatment with chemo-virotherapy and MEK inhibitor: A mathematical model of Caputo fractional differential operator

Alexandria Engineering Journal, 2023
Mitogen-activated protein kinase (MEK) inhibitors and oncolytic virotherapy are identified as promising cancer therapies that can enhance the efficacy of other cancer treatments.
M. Moksud Alam, S.M.E.K. Chowdhury, J.T. Chowdhury, Mohammad Mahmud Hasan, M.A. Ullah, Shams Forruque Ahmed   +5 more
doaj  

The Use of Gut Organoids: To Study the Physiology and Disease of the Gut Microbiota

Journal of Cellular and Molecular Medicine, Volume 29, Issue 4, February 2025.
ABSTRACT The intestinal flora has attracted much attention in recent years. An imbalance in the intestinal flora can cause not only intestinal diseases but also cause a variety of parenteral diseases, such as endocrine diseases, nervous system diseases and cardiovascular diseases.
Ya Deng, Xiaolu Yuan, XianMin Lu, Jiangbo Wu, Chen Luo, Ting Zhang, Qi Liu, Siqi Tang, Zhuo Li, Xingyi Mu, Yanxia Hu, Qian Du, Jingyu Xu, Rui Xie   +13 more
wiley   +1 more source

Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy

Molecular Cancer, 2020
As a promising therapeutic strategy, oncolytic virotherapy has shown potent anticancer efficacy in numerous pre-clinical and clinical trials. Oncolytic viruses have the capacity for conditional-replication within carcinoma cells leading to cell death via
Bin Zhang, P. Cheng
semanticscholar   +1 more source

Decorin Expressed From Herpes Simplex Virus Vector Improves Oncolytic Efficacy in Lung Adenocarcinoma Cells

Proteoglycan Research, Volume 3, Issue 1, January-March 2025.
ABSTRACT Decorin (DCN) is a small extracellular proteoglycan with significant oncosuppressive activity. Lung adenocarcinoma is commonly devoid of DCN expression and is a leading cause of cancer mortality globally. As a proof‐of‐concept study for evaluating the oncosuppressive potential of DCN expression in lung adenocarcinoma cells, we constructed an ...
Fanny Frejborg, Jussi Palomäki, Kiira Kalke, Julius Orpana, Oliver Koivisto, Henrik Paavilainen, Jessica M. Rosenholm, Hongbo Zhang, Veijo Hukkanen, Hannu Järveläinen   +9 more
wiley   +1 more source

Genetically Engineered Cell Membrane Nanovesicles for Oncolytic Adenovirus Delivery: A Versatile Platform for Cancer Virotherapy.

Nano letters (Print), 2019
Currently, various oncolytic adenoviruses (OA) are being explored in both preclinical and clinical virotherapy. However, the pre-existing neutralizing antibodies (nAbs) and poor targeting delivery are major obstacles for systemically administered OA ...
Peng Lv, Xuan Liu, Xiaomei Chen, Chao Liu, Yang Zhang, Chengchao Chu, Junqing Wang, Xiaoyong Wang, Xiaoyuan Chen, G. Liu   +9 more
semanticscholar   +1 more source

Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression

OncoImmunology, 2019
Antitumor cytotoxic T lymphocytes (CTLs) are essential for immune surveillance, yet the blockade of eliciting such CTLs during oncolytic virotherapy remains incompletely understood.
Zhiwu Tan, Li Liu, Mei Sum Chiu, Ka-Wai Cheung, Chi Wing Yan, Zhe Yu, Boon Kiat Lee, Wan Liu, Kwan Man, Zhiwei Chen   +9 more
doaj   +1 more source

Abstracts

Molecular Oncology, Volume 19, Issue S1, Page 1-895, June 2025.
Abstracts submitted to the ‘EACR 2025 Congress: Innovative Cancer Science’, from 16–19 June 2025 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Talimogene laherparepvec: First in class oncolytic virotherapy

Human Vaccines & Immunotherapeutics, 2018
Oncolytic viruses represent a novel drug class in which native or modified viruses mediate tumor regression through selective replication within and lysis of tumor cells as well as induction of systemic antitumor immunity capable of eradicating tumor at ...
R. Conry, Brian C. Westbrook, Svetlana B. McKee, T. G. Norwood   +3 more
semanticscholar   +1 more source

Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial

Nature Network Boston, 2023
H. Soliman, D. Hogue, H. Han, Blaise Mooney, R. Costa, Marie Catherine Lee, B. Niell, Angela Williams, A. Chau, Shannon Falcon, A. Soyano, Avan J Armaghani, N. Khakpour, R. Weinfurtner, S. Hoover, J. Kiluk, C. Laronga, M. Rosa, H. Khong, B. Czerniecki   +19 more
semanticscholar   +1 more source

Editorial: Oncolytic virotherapy

Frontiers in Molecular Biosciences, 2023
Ahmed Majeed Al-Shammari, Pier Paolo Piccaluga, Pier Paolo Piccaluga   +2 more
openaire   +3 more sources